A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: myeloperoxidase-positive and myeloid antigen-negative

Leukemia Research
G SpecchiaV Liso

Abstract

We report a case of acute myeloid leukemia (AML-M2) expressing myeloperoxidase (MPO) but no myeloid antigens. A few cases with this discordant phenotype have been reported and an association has been suggested between the lack of CD13 and CD33 in MPO positive AML and the presence of t(8;21). Cytogenetic and molecular analyses performed in our case showed 48,XY,+Y,+8,t(2;9)(q14;p12). We believe that combined approaches can contribute to detect particular AL cases like the present one, that confirms the heterogeneity of AML. However, further studies are needed to clarify the relationship between phenotypic aberrations and cytogenetic abnormalities.

References

Jun 1, 1992·British Journal of Haematology·A Urbano-IspizuaE Montserrat
Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Aug 1, 1987·American Journal of Hematology·H G DrexlerA V Hoffbrand
Jan 1, 1995·Cytogenetics and Cell Genetics·R AntonacciM Rocchi
Nov 1, 1996·Leukemia Research·S A BrownR Ireland
Mar 1, 1997·Placenta·T YanagawaT Kudo
Feb 18, 1998·Current Opinion in Oncology·M R Baer
Jun 8, 2001·Journal of the American Veterinary Medical Association·B R SchmidtD W Knapp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.